Li Li, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 3 carriers
- Office
- 1
- Since medical school
- 31 years
- Graduated 1995
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
10 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Li’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A145066 · Current
Licensed to practise in California · since 2016 · expires 2028-08-31 · Anhwei Medical College Aka Anhui Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Medical Oncology
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$11,007
Medicare paid this office $11,007 for 67 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 15 | $3,022 | $126 |
| Return visit (30+ min) | 24 | $2,270 | $67 |
Who their Medicare patients are
67 Original Medicare patients in 2024. Average age 72 · Women 55% · Also on Medicaid 76% · Health risk score 2.01. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Cancer 54% · Diabetes 49% · Chronic kidney disease 30% · Coronary heart disease 24% · Depression 24% · Heart failure 22% · Atrial fibrillation 19%.
The office billed $100,746, Medicare allowed $14,993 and paid $11,007; for 114 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 67 | 114 | 72 | 2.01 | $100,746 | $11,007 |
| 2023 | 66 | 151 | 72 | 2.31 | $104,688 | $13,277 |
| 2022 | 80 | 169 | 72 | 2.39 | $95,582 | $13,940 |
| 2021 | 70 | 174 | 72 | 2.04 | $73,106 | $13,911 |
| 2020 | 218 | 906 | 70 | 2.79 | $296,808 | $91,750 |
| 2019 | 248 | 1,113 | 70 | 2.57 | $347,905 | $128,971 |
| 2018 | 207 | 705 | 71 | 2.20 | $229,873 | $77,598 |
| 2017 | 68 | 142 | 68 | 1.97 | $48,764 | $15,383 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 11 | $3,059 | $127 |
| Return visit (30+ min) | 24 | $2,789 | $73 |
| Short return visit (20+ min) | 12 | $976 | $54 |
2022: 6 services
| Long return visit (40+ min) | 17 | $2,749 | $125 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,482 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,007 | $106 |
| Return visit (30+ min) | 14 | $1,450 | $85 |
| Telephone medical discussion with physician, 5-10 minutes | 26 | $1,351 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,239 | $77 |
2021: 5 services
| Telephone medical discussion with physician, 21-30 minutes | 28 | $4,956 | $94 |
| Long return visit (40+ min) | 16 | $2,202 | $138 |
| Telephone medical discussion with physician, 5-10 minutes | 28 | $2,122 | $34 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,573 | $143 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,319 | $88 |
2020: 11 services
| Long return visit (40+ min) | 71 | $48,109 | $113 |
| Return visit (30+ min) | 76 | $18,858 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,356 | $82 |
| New patient visit (60+ min) | 29 | $4,648 | $160 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,209 | $168 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $3,737 | $107 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 20 | $3,136 | $157 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,245 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $970 | $57 |
| Short return visit (20+ min) | 17 | $968 | $48 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 17 | $241 | $11 |
2019: 9 services
| Long return visit (40+ min) | 95 | $55,509 | $114 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 40 | $36,221 | $157 |
| Return visit (30+ min) | 71 | $10,615 | $85 |
| New patient visit (60+ min) | 38 | $6,295 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $5,925 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 58 | $5,630 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,799 | $160 |
| Short return visit (20+ min) | 17 | $1,289 | $50 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $901 | $64 |
2018: 9 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 25 | $20,698 | $157 |
| Long return visit (40+ min) | 53 | $15,165 | $89 |
| Long return visit (40+ min) | 40 | $11,770 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,523 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $4,892 | $84 |
| Return visit (30+ min) | 49 | $4,747 | $62 |
| New patient visit (60+ min) | 29 | $3,553 | $123 |
| Return visit (30+ min) | 23 | $2,564 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,875 | $110 |
2017: 5 services
| Long return visit (40+ min) | 17 | $3,333 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,955 | $164 |
| New patient visit (60+ min) | 21 | $2,864 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,692 | $85 |
| Return visit (30+ min) | 17 | $1,148 | $64 |
Medicaid work
$4,776 in 2024
Medicaid paid $4,776 for 535 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 185 | $2,792 |
| Return visit (30+ min) | 64 | $1,984 |
| Medication list documented in medical record (COA) | 201 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 32 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 53 | $0 |
| 2024 | 535 | 5 | 34 | $4,776 |
| 2023 | 194 | 3 | 19 | $1,786 |
| 2022 | 265 | 3 | 22 | $3,654 |
| 2021 | 186 | 2 | 19 | $3,341 |
| 2020 | 15 | 1 | 13 | $380 |
| 2019 | 99 | 2 | 16 | $3,199 |
| 2018 | 66 | 3 | 14 | $1,267 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 131 | $1,527 |
| Return visit (30+ min) | 50 | $259 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 13 | $0 |
2022
| Long return visit (40+ min) | 130 | $2,164 |
| Return visit (30+ min) | 110 | $1,269 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 25 | $221 |
2021
| Return visit (30+ min) | 124 | $2,177 |
| Long return visit (40+ min) | 62 | $1,163 |
2020
| Return visit (30+ min) | 15 | $380 |
2019
| Long return visit (40+ min) | 75 | $2,485 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $714 |
2018
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 28 | $845 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 23 | $421 |
| Hospital outpatient clinic visit for assessment and management of a patient | 15 | $0 |
Drugs they prescribed that Part D paid
$1,603,678
Pharmacies billed $1,603,678 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 274) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
131 generic and 143 brand-name prescriptions · $1,603,678 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 33 | $528,679 | $16,021 |
| Kisqali | 25 | $320,818 | $12,833 |
| Xtandi | 23 | $315,863 | $13,733 |
| Krazati | 11 | $232,503 | $21,137 |
| Verzenio | 12 | $154,517 | $12,876 |
See all 10 drugs
| Tagrisso | 33 | $528,679 | $16,021 |
| Kisqali | 25 | $320,818 | $12,833 |
| Xtandi | 23 | $315,863 | $13,733 |
| Krazati | 11 | $232,503 | $21,137 |
| Verzenio | 12 | $154,517 | $12,876 |
| Orgovyx | 11 | $25,730 | $2,339 |
| Letrozole | 28 | $498 | $18 |
| Anastrozole | 15 | $192 | $13 |
| Loperamide | 17 | $175 | $10 |
| Gabapentin | 24 | $98 | $4 |
Year by year
| 2024 | 274 | 36 | 0% (0) | 52% | $1,603,678 |
| 2023 | 205 | 29 | None | 45% | $1,056,131 |
| 2022 | 164 | 32 | None | 27% | $513,050 |
| 2021 | 155 | 36 | None | 15% | $206,138 |
| 2020 | 597 | 72 | 6% (37) | 24% | $1,347,155 |
| 2019 | 416 | 81 | 7% (27) | 28% | $1,211,609 |
| 2018 | 232 | 53 | 10% (23) | 24% | $650,286 |
| 2017 | 45 | 13 | None | None | $78,519 |
| 2014 | 145 | 22 | None | 18% | $6,677 |
| 2013 | 176 | 26 | 0% (0) | 21% | $8,465 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Tagrisso | 38 | $636,987 | $16,763 |
| Orgovyx | 13 | $35,219 | $2,709 |
| Letrozole | 23 | $1,017 | $44 |
| Anastrozole | 14 | $645 | $46 |
| Loperamide | 14 | $183 | $13 |
2022: 4 drugs
| Tagrisso | 27 | $439,894 | $16,292 |
| Letrozole | 25 | $782 | $31 |
| Ondansetron | 17 | $351 | $21 |
| Prochlorperazine Maleate | 11 | $235 | $21 |
2021: 5 drugs
| Aprepitant | 15 | $7,143 | $476 |
| Letrozole | 11 | $658 | $60 |
| Prochlorperazine Maleate | 22 | $259 | $12 |
| Dexamethasone | 18 | $187 | $10 |
| Ondansetron | 17 | $112 | $7 |
2020: 15 drugs
| Mekinist | 20 | $250,461 | $12,523 |
| Tagrisso | 15 | $223,417 | $14,894 |
| Tafinlar | 20 | $209,387 | $10,469 |
| Ibrance | 13 | $158,582 | $12,199 |
| Everolimus | 13 | $158,372 | $12,182 |
| Eliquis | 14 | $6,875 | $491 |
| Potassium Chloride | 28 | $1,564 | $56 |
| Prochlorperazine Maleate | 67 | $962 | $14 |
| Ondansetron | 70 | $875 | $13 |
| Ondansetron Odt | 16 | $768 | $48 |
| Dexamethasone | 47 | $620 | $13 |
| Hydrocodone-Acetaminophen | 26 | $523 | $20 |
| Mirtazapine | 35 | $275 | $8 |
| Pantoprazole | 25 | $200 | $8 |
| Furosemide | 13 | $44 | $3 |
2019: 11 drugs
| Tagrisso | 29 | $438,327 | $15,115 |
| Afinitor | 12 | $195,717 | $16,310 |
| Mekinist | 14 | $160,916 | $11,494 |
| Tafinlar | 14 | $150,025 | $10,716 |
| Ibrance | 12 | $139,413 | $11,618 |
| Ondansetron | 67 | $890 | $13 |
| Prochlorperazine Maleate | 57 | $617 | $11 |
| Dexamethasone | 20 | $384 | $19 |
| Potassium Chloride | 16 | $342 | $21 |
| Hydrocodone-Acetaminophen | 15 | $299 | $20 |
| Mirtazapine | 18 | $246 | $14 |
2018: 6 drugs
| Tagrisso | 14 | $215,342 | $15,382 |
| Ondansetron | 42 | $637 | $15 |
| Prochlorperazine Maleate | 48 | $456 | $10 |
| Morphine Sulfate Er | 12 | $304 | $25 |
| Potassium Chloride | 11 | $167 | $15 |
| Dexamethasone | 11 | $162 | $15 |
2014: 1 drug
| Glipizide | 14 | $42 | $3 |
2013: 4 drugs
| Januvia | 11 | $2,844 | $259 |
| Simvastatin | 11 | $105 | $10 |
| Enalapril Maleate | 16 | $98 | $6 |
| Amlodipine Besylate | 12 | $74 | $6 |
Money from drug and device companies
$66 in 2025
| 2025 | 1 | 1 | None | $66 |
| 2021 | 2 | 2 | None | $40 |
| 2020 | 3 | 4 | None | $64 |
| 2019 | 7 | 12 | None | $483 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | None | $66 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-25 | None | $66 |
See earlier years (2021, 2020, 2019)
2021: $40
| GlaxoSmithKline | Blenrep | $29 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $64
| E.R. Squibb & Sons L.L.C. | Opdivo | $26 | 2 payments
|
| GlaxoSmithKline | Zejula | $21 | 1 payment
|
| Genentech USA | Tecentriq | $18 | 1 payment
|
2019: $483
| Astellas Pharma US | None | $183 | 2 payments
|
| Eisai | Lenvima | $155 | 4 payments
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $63 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $35 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $17 | 1 payment
|
| Genentech USA | Tecentriq | $17 | 1 payment
|
| Gilead Sciences | None | $13 | 1 payment
|
Professional record
- NPI
- 1528355120
- Licence
- CA A145066California A145066: Current · expires 2028-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2011-07-02
- NPI last updated
- 2020-01-15
- NPI record certified
- 2020-01-15
This is when the NPI record was last certified, not a medical board exam.